Tenderwize
Retour à la recherche

Open-house rebate agreement for lisdexamfetamine

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2026 · 3 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lisdexamfetamin (ATC-Code nach WHO: N06BA12)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The structured data states an end date of 31.08.2026, while the XML notice change text says the open-house procedure en...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Submission deadline in 3 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2026
  • Conclusion of non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for the active substance lisdexamfetamine.
  • Open-house model: any interested pharmaceutical company may join during the participation period if it meets and accepts the conditions.
Afficher le résumé complet

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for lisdexamfetamine (ATC N06BA12) with AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No contract value is stated, no minimum purchase is guaranteed, and the agreement can end early if exclusive rebate agreements are concluded. Participation documents are available via DTVP, but no extracted procurement document text beyond the TED XML notice was provided.

Risques

The structured data states an end date of 31.08.2026, while the XML notice change text says the open-house procedure en...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Submission deadline in 3 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only pharmaceutical undertakings within the meaning of Section 4(18) AMG for the offered medicinal products may participate.

Eligibility

  • Submit the completed declaration on the absence of exclusion grounds with the participation documents.

Administrative

  • Submit the declaration regarding Russia sanctions compliance using the provided form.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for lisdexamfetamine

Non-exclusive rebate agreement for medicines containing lisdexamfetamine (ATC N06BA12). The lot is a supply contract under an open-house model; no exclusivity, no individual negotiations, and demand/volume are unknown. Performance/place of performance is indicated as Dresden, Germany, with broader reference to Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Aug 2025 - Aug 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 31, 2026

Détails de la procédure

Date de publication
02 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
800535-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30